Navigation Links
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
Date:4/24/2008

ogy platform for therapeutic antibody fragments, we started preclinical development of ESBA105 in mid 2006. Now to move this swiftly into the clinic is a truly exciting time for the company. ESBA105 represents a new generation of antibody fragment therapeutics that have favourable biochemical properties over earlier classes of antibody fragments, such as high stability, solubility and high monomeric content. This allows us to deliver the drug topically, without any need to stabilize or modify the protein. Thanks to the small protein size as compared to conventional antibodies, ESBA105 efficiently penetrates into all segments of the eye, which results in a high local concentration where the drug is needed to inhibit inflammation. As this is associated with low systemic drug exposure, this novel therapeutic approach has a very low risk of provoking systemic adverse effects."

ESBATech is the first and only company to date that has successfully screened and characterized the entire human pool (1.5 million) of naturally occurring variable immunoglobulin (VH and VL) domains to select highly stable, soluble and monomeric single-chain antibody fragments frameworks. The company is advancing a pipeline of novel, antibody fragment therapeutics for topical and/or local delivery, to ensure safe and convenient patient therapy.

About ESBATech AG

ESBATech AG is a Zurich, Switzerland-based, privately held drug discovery and development company focused on advancing antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery. Current venture investors include SV Life Sciences,
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Tasly Pharmaceuticals, Inc., the world,s ... announced today the launch of Deepure. ... address men and women concerned with supporting their ... old age while helping keep their health care ... and herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, ...
(Date:9/30/2014)... 2014  Decision Resources Group finds that the markets ... , Russia , ... (BRIC) will see robust expansion as these economies expand ... procedures. Although revenues will be somewhat impeded by poor ... approval times and demand for low-cost products, the market ...
(Date:9/30/2014)... --  Easy Breathe , the fastest growing online ... now offers the revolutionary AirSense CPAPs by ... apnea therapy devices with internal cellular modems.  This break-through ... share real-time data on each user,s quality of sleep ... addition, the internal modem allows the CPAP to be ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... startup  PhotOral™  announced today it has licensed a ... to develop a novel intraoral device that uses ... dental plaque microorganisms. The agreement empowers ... the $7 billion oral care market.  PhotOral Founder ...
... R.I., Dec. 15, 2011  CVS Caremark announced today ... Chain Distinction Award North America in the Logistics ... week at the annual Supply Chain Logistics Summit ... http://photos.prnewswire.com/prnh/20090226/NE75914LOGO ) The Logistics Best ...
Cached Medicine Technology:Life Sciences Startup PhotOral Licenses Patented Oral Blue-Light Technology From Forsyth Institute 2CVS Caremark Receives Logistics Best Practice Award at 2011 Supply Chain Logistics Summit 2CVS Caremark Receives Logistics Best Practice Award at 2011 Supply Chain Logistics Summit 3
(Date:9/30/2014)... Research by UC Irvine immunologists reveals new information ... a vital process that determines how the body,s ability ... of Nature Immunology , neurology professor Dr. Michael ... Immunology colleagues describe a critical mechanism underlying how T ... , A T cell is a type of blood ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... by Blue Star Nutraceuticals designed to help maximize lean, ... that optimizes the body’s absorption of glucose has caught ... , “The main purpose behind Glycodrive is to ... builds lean muscle,” reports Michaels. “Carbs are essential in ...
(Date:9/30/2014)... Elevate , the latest product from ... and out of the gym by providing natural ingredients that ... of Shane Michaels, prompting an investigative review. , “When ... most people simply just don’t have the ability to perform ... work, getting the motivation to finish a project, or even ...
(Date:9/30/2014)... For most families, fall means back-to-school pictures and ... annual festival. For millions of children, fall also means ... infection Enterovirus D68. , While symptoms mimic the ... especially children with weakened immune systems – can develop ... prompting hospitals across the country to enact visitor restrictions. ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set to open ... RMS welcomes the launch of an entirely new facility, ... new treatment center for the Lung Institute. , ... Nashville, the hope is to bring awareness to those ... undiagnosed. With Nashville being a hub for medical technology, ...
Breaking Medicine News(10 mins):Health News:UCI study uncovers important process for immune system development 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:As Hospitals Combat Enterovirus Outbreaks, Patients and Families Turn to “Virtual Visits” with CaringBridge 2Health News:Regenerative Medicine Solutions Expanding 2
... , , BALTIMORE, ... groups and industry to educate expecting parents about the medical significance ... three out of every four pregnant women still consider themselves only ... on stem cell science and policy found that a proprietary, web-based ...
... ROCHESTER, N.Y., Sept. 23 Bausch & Lomb, the ... J. Palmisano have joined its board of directors. , , ... and relevant experience," said Gerald M. Ostrov, chairman and chief executive ... positioned for long-term growth. We welcome Kerry and Bob and look ...
... PLAINS, N.Y., SEPT. 23, 2009 -- Pregnant women should be ... the vaccines become available this year to protect them against ... to eight leading national maternal and infant health organizations. ... College of Obstetricians and Gynecologists, the American Academy of Pediatrics, ...
... Agent-based models (ABMs) are powerful computer-simulation modeling techniques ... of biological phenomena, such as tumor growth, the ... through a population. Researchers will gather Dec. ... Biological Synthesis (NIMBioS) on the University of Tennessee, ...
... , ... for November 17-19, 2009, in Miami, FL , ... Portland, Maine (PRWEB) September 23, 2009 -- IntertechPira and ... 2009, the industry,s leading event focusing on biotechnology, engineering and alternative energy applications as ...
... WAYNE, Pa., Sept. 23 RRY Publications announced the preliminary ... the premier gathering of stem cell company executives, scientists and ... The Summit is an intensive one-day event where attendees explore ... stem cell product commercialization, and the latest investment opportunities within ...
Cached Medicine News:Health News:Data Released at an International Stem Cell Meeting Highlights Effectiveness of New Patient Education System Developed to Support Federal and State Guidelines on Cord Blood Education 2Health News:Data Released at an International Stem Cell Meeting Highlights Effectiveness of New Patient Education System Developed to Support Federal and State Guidelines on Cord Blood Education 3Health News:R. Kerry Clark and Robert J. Palmisano Join Bausch & Lomb Board of Directors 2Health News:Pregnant women need flu shots 2Health News:Agenda Announced for Ionic Liquids 2009 2Health News:5th Annual Stem Cell Summit Set for Feb. 16 in New York City 2Health News:5th Annual Stem Cell Summit Set for Feb. 16 in New York City 3